{"entity":{"id":"patricia-pautier","kind":"person","name":"Patricia Pautier","aka":[],"tldr":"Paris oncologist who led LMS-04, the trial that showed doxorubicin plus trabectedin lengthens survival in advanced leiomyosarcoma compared with doxorubicin alone.","summary":"Patricia Pautier is a medical oncologist at Gustave Roussy who treats sarcomas and gynaecological cancers. She was first author of the 2022 Lancet Oncology report of the French Sarcoma Group LMS-04 trial, in which doxorubicin plus trabectedin followed by trabectedin maintenance improved progression-free survival compared with doxorubicin alone as first-line treatment for metastatic or unresectable leiomyosarcoma; the 2024 update showed an overall survival gain.","asOf":"2026-09-18","links":[],"tags":["sarcoma","trialist"],"related":[],"cancers":["leiomyosarcoma","extremity-soft-tissue-sarcoma","retroperitoneal-sarcoma","sarcoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["gustave-roussy"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022"],"journals":[],"dependsOn":[],"notes":[],"role":"Medical oncologist, Gustave Roussy","institutionId":"gustave-roussy","specialisms":["Leiomyosarcoma","Gynaecological sarcomas","Ovarian cancer"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Pautier%5BAuthor%5D"}],"papers":[]},"route":"/people/patricia-pautier/","neighbours":{"cancer":[{"id":"leiomyosarcoma","kind":"cancer","name":"Leiomyosarcoma","route":"/cancers/leiomyosarcoma/"},{"id":"retroperitoneal-sarcoma","kind":"cancer","name":"Retroperitoneal sarcoma","route":"/cancers/retroperitoneal-sarcoma/"},{"id":"sarcoma","kind":"cancer","name":"Sarcomas (soft tissue, bone, GIST)","route":"/cancers/sarcoma/"},{"id":"extremity-soft-tissue-sarcoma","kind":"cancer","name":"Soft tissue sarcoma of the extremity (localised and advanced)","route":"/cancers/extremity-soft-tissue-sarcoma/"}],"institution":[{"id":"gustave-roussy","kind":"institution","name":"Gustave Roussy","route":"/institutions/gustave-roussy/"}],"paper":[{"id":"paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022","kind":"paper","name":"LMS-04: doxorubicin plus trabectedin followed by trabectedin maintenance versus doxorubicin alone in metastatic leiomyosarcoma","route":"/key-papers/paper-lms-04-doxorubicin-trabectedin-lancet-oncol-2022/"}]}}